MedTrace Logo

Benefits of Nigella Sativa in Children With Beta Thalassemia Major

NCT02816957 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-04-26

No results posted yet for this study

Summary

Evaluate the therapeutic effects health benefits, and immunological effect of Nigella sativa in children with beta thalassemia major.

Conditions

  • Nigella Sativa With Beta Thalassemia Major

Interventions

DRUG

nigella sativ

nigella sativa powder (2 gm/day) for 3 consecutive months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohamed Ramadan ELshanshory, prof · professor of pediatrics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02816957 on ClinicalTrials.gov